Min Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Min Zhou has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Qintai Yang
Department of Otolaryngology, The Institute of the Third Affiliated Hospital of Sun Yat-Sen University, Tianhe District, Guangzhou, China
5 shared publications - Yan Ruan
Department of Otolaryngology Head and Neck Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, China
5 shared publications Jia-Jun Zhang
First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publicationsQin-Dong Liu
First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publications- Ruizhi Wang
Department of Otolaryngology The Third Affiliated Hospital of Sun Yat‐sen University Guangzhou China
3 shared publications Yongchun Wang
Department of Otolaryngology, The Institute of The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
3 shared publications
Latest Publications
- 25 August 2026
- Published by Taylor & Francis in Journal of Asthma
- p. 1-16
Xiaoqinglong decoction attenuates allergic rhinitis comorbid with asthma via modulation of the ALOX15/GPX4 axis
Allergic airway inflammation encompasses upper airway disorders such as allergic rhinitis (AR) and lower airway conditions such as asthma. Epidemiological studies report that AR affects approximate...
- 25 August 2026
- Published by Taylor & Francis in Journal of Asthma
- p. 1-16
Xiaoqinglong decoction attenuates allergic rhinitis comorbid with asthma via modulation of the ALOX15/GPX4 axis
Allergic airway inflammation encompasses upper airway disorders such as allergic rhinitis (AR) and lower airway conditions such as asthma. Epidemiological studies report that AR affects approximate...
- Open Access
- 3 July 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1512156
Case Report: A middle-aged woman with mediastinal follicular dendritic cell sarcoma complicated by paraneoplastic pemphigus
As a relatively rare malignant entity, follicular dendritic cell sarcoma (FDCS) of the mediastinum currently suffers from insufficient clinical characterization, warranting more comprehensive studies to optimize therapeutic strategies. The initial symptoms of FDCS are often related to the respiratory system. It is particularly rare for the disease to present initially as recurrent ulcers in the oropharynx, which eventually led to a diagnosis of paraneoplastic pemphigus. Here, we report a case of a young female patient diagnosed with mediastinal FDCS associated with paraneoplastic pemphigus. The patient presented with recurrent pharyngeal ulcers and was diagnosed with mediastinal FDCS associated with paraneoplastic pemphigus 10 months later through imaging and pathological examinations.
- 3 July 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1512156
Open AccessCase Report: A middle-aged woman with mediastinal follicular dendritic cell sarcoma complicated by paraneoplastic pemphigus
As a relatively rare malignant entity, follicular dendritic cell sarcoma (FDCS) of the mediastinum currently suffers from insufficient clinical characterization, warranting more comprehensive studies to optimize therapeutic strategies. The initial symptoms of FDCS are often related to the respiratory system. It is particularly rare for the disease to present initially as recurrent ulcers in the oropharynx, which eventually led to a diagnosis of paraneoplastic pemphigus. Here, we report a case of a young female patient diagnosed with mediastinal FDCS associated with paraneoplastic pemphigus. The patient presented with recurrent pharyngeal ulcers and was diagnosed with mediastinal FDCS associated with paraneoplastic pemphigus 10 months later through imaging and pathological examinations.
- Open Access
- 22 January 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (1) , e70030
Allergen sensitization patterns: Allergic rhinitis with multimorbidity versus alone—A real‐world study
Background: Allergic rhinitis (AR) multimorbidity may need to be considered a specific disease because of distinct clinical and immunological differences from AR alone. Allergic multimorbidity often involves polysensitization, where allergen‐specific immunoglobulin E (IgE) plays a significant role.Objective: This study aims to explore differences in allergen IgE sensitization patterns between AR alone and AR multimorbidity.Methods: A real‐world case‐control study was conducted with patients diagnosed with AR. Multivariate logistic regression analyzed the associations between AR multimorbidity and allergen sensitivity, allergen‐specific IgE levels, and the count of positive allergens.Results: A cohort of 2275 patients with AR was included, of which 1100 (48.4%) presented with AR alone, while 1175 (51.6%) exhibited AR multimorbidity. Patients with AR multimorbidity had a more diverse allergen profile than those with AR alone. An increased number of positive ingested allergens had a higher odds ratio (OR) for AR multimorbidity compared with inhaled allergens (1.46 vs. 1.96) across all phenotypes. Sensitization to allergens and their allergen‐specific IgE levels, including dust mites, cat dander, and milk (p < 0.05), were associated with AR multimorbidity. In children, cat and dog dander were significant allergens associated with AR multimorbidity (p < 0.05).Conclusions: Allergen sensitization patterns in AR multimorbidity differ from those in AR alone. Polysensitization, particularly to ingested allergens, increases the risk of allergic multimorbidity. The risk of allergic multimorbidity also increases with specific allergen positivity and higher allergen‐specific IgE levels.
- 22 January 2025
- Published by Wiley in Clinical and Translational Allergy
- Vol. 15 (1) , e70030
Open AccessAllergen sensitization patterns: Allergic rhinitis with multimorbidity versus alone—A real‐world study
Background: Allergic rhinitis (AR) multimorbidity may need to be considered a specific disease because of distinct clinical and immunological differences from AR alone. Allergic multimorbidity often involves polysensitization, where allergen‐specific immunoglobulin E (IgE) plays a significant role.Objective: This study aims to explore differences in allergen IgE sensitization patterns between AR alone and AR multimorbidity.Methods: A real‐world case‐control study was conducted with patients diagnosed with AR. Multivariate logistic regression analyzed the associations between AR multimorbidity and allergen sensitivity, allergen‐specific IgE levels, and the count of positive allergens.Results: A cohort of 2275 patients with AR was included, of which 1100 (48.4%) presented with AR alone, while 1175 (51.6%) exhibited AR multimorbidity. Patients with AR multimorbidity had a more diverse allergen profile than those with AR alone. An increased number of positive ingested allergens had a higher odds ratio (OR) for AR multimorbidity compared with inhaled allergens (1.46 vs. 1.96) across all phenotypes. Sensitization to allergens and their allergen‐specific IgE levels, including dust mites, cat dander, and milk (p < 0.05), were associated with AR multimorbidity. In children, cat and dog dander were significant allergens associated with AR multimorbidity (p < 0.05).Conclusions: Allergen sensitization patterns in AR multimorbidity differ from those in AR alone. Polysensitization, particularly to ingested allergens, increases the risk of allergic multimorbidity. The risk of allergic multimorbidity also increases with specific allergen positivity and higher allergen‐specific IgE levels.
- Open Access
- 21 December 2024
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 186 (8) , 733-746
Advanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis
Introduction: Emerging evidence has underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic. Methods: The databases of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention. Results: 2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated to have the highest efficacy in reducing asthmatic exacerbations, improving lung function, and improving patients’ quality of life, with the SUCRA values of 0.956, 0.999, and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930. Conclusions: In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
- 21 December 2024
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 186 (8) , 733-746
Open AccessAdvanced Biologic Therapies in the Management of Asthma in Children and Adolescents: A Comprehensive Network Meta-Analysis
Introduction: Emerging evidence has underscored the positive impact of biologics on asthmatic patients. However, there is a pressing need to verify their therapeutic efficacy in children and adolescents with asthma. To address this, we conducted a network meta-analysis (NMA) to evaluate the efficacy and safety of biologics in the asthma management of this demographic. Methods: The databases of PubMed, Embase, Web of Science, and Cochrane Library were comprehensively searched in our study until May 29, 2024. Only randomized controlled trials were included to estimate the value of biologics on asthmatic children and adolescents. Data extraction and risk of bias assessment were independently performed by two researchers. Outcomes were analyzed by a fixed effects model, and the surface under the cumulative ranking (SUCRA) scores were calculated to determine the likelihood of each biologic being the most effective intervention. Results: 2,672 patients were included for comparing four different biologics (dupilumab, omalizumab, lebrikizumab, and mepolizumab) with a placebo. Dupilumab has been demonstrated to have the highest efficacy in reducing asthmatic exacerbations, improving lung function, and improving patients’ quality of life, with the SUCRA values of 0.956, 0.999, and 0.897, respectively. Omalizumab showed the best safety potential by reducing the risk of adverse and severe events, with the SUCRA values of 0.876 and 0.930. Conclusions: In this NMA, focusing on biologics that target type 2 inflammation in childhood and adolescent asthma, four biologics demonstrated a favorable safety profile. Notably, dupilumab emerged as the most effective, while omalizumab was identified as the safest therapy. Further studies must be conducted in order to confirm these findings.
- Open Access
- 4 March 2024
- Published by Springer Nature in Chinese Medicine
- Vol. 19 (1) , 1-18
Platycodon D protects human nasal epithelial cells from pyroptosis through the Nrf2/HO-1/ROS signaling cascade in chronic rhinosinusitis
Background: Pyroptosis has been demonstrated being closely associated with the inflammatory progression in chronic rhinosinusitis (CRS). However, platycodon D (PLD) has emerged as a key anti-inflammatory mediator in the inflammatory progression of various respiratory diseases. This study aims at investigating whether PLD could reduce inflammatory progression of CRS by inhibiting pyroptosis. Methods: Nasal mucosal tissues from patients with CRS and the control group (simple nasal septal deviation) were analyzed for morphological difference using hematoxylin & eosin staining and for the expression of pyroptosis-related makers by immunofluorescence (IF). Human nasal epithelial cells (HNEpCs) were cultured and co-stimulated with lipopolysaccharide (LPS)/adenosine triphosphate (ATP) to construct an in vitro cellular model simulating CRS. After pretreatment with PLD, EthD-I staining, TUNEL staining, transmission electron microscopy (TEM), and GSDMD-NT detection were performed to evaluate pyroptosis markers. The NLRP3 inflammasome was detected by IF and western blotting (WB). Reactive oxygen species (ROS) were detected by H2DCFDA staining, and mitochondrial membrane potential was evaluated by JC-1 staining. Mitochondrial morphology and structure were observed using TEM. The Nrf2/HO-1 antioxidant signaling pathway was detected using WB. Results: The nasal mucosa structure of patients with CRS exhibited significant damage, with a marked increase in the expression of pyroptosis-related proteins compared with the control group. LPS/ATP co-stimulation resulted in an increased expression of IL-18 and IL-1β in HNEpCs, causing significant damage to nuclear and cell membranes, GSDMD-NT accumulation around the cell membrane, and intracellular NLRP3 inflammasome activation. Furthermore, it led to increased ROS expression, significantly decreased mitochondrial membrane potential, and damaged mitochondrial structure. However, pretreatment with PLD significantly reversed the aforementioned trends and activated the Nrf2/HO-1 antioxidant signaling pathway. Conclusions: The results of this study confirm that NLRP3-mediated pyroptosis plays a crucial role in the pathological process of nasal mucosal impairment in patients with CRS. PLD inhibits NLRP3-mediated pyroptosis, preventing inflammatory damage in HNEpCs of patients with CRS by activating the Nrf2/HO-1 antioxidant signaling pathway, which in turn reduces ROS production and ameliorates mitochondrial damage.
- 4 March 2024
- Published by Springer Nature in Chinese Medicine
- Vol. 19 (1) , 1-18
Open AccessPlatycodon D protects human nasal epithelial cells from pyroptosis through the Nrf2/HO-1/ROS signaling cascade in chronic rhinosinusitis
Background: Pyroptosis has been demonstrated being closely associated with the inflammatory progression in chronic rhinosinusitis (CRS). However, platycodon D (PLD) has emerged as a key anti-inflammatory mediator in the inflammatory progression of various respiratory diseases. This study aims at investigating whether PLD could reduce inflammatory progression of CRS by inhibiting pyroptosis. Methods: Nasal mucosal tissues from patients with CRS and the control group (simple nasal septal deviation) were analyzed for morphological difference using hematoxylin & eosin staining and for the expression of pyroptosis-related makers by immunofluorescence (IF). Human nasal epithelial cells (HNEpCs) were cultured and co-stimulated with lipopolysaccharide (LPS)/adenosine triphosphate (ATP) to construct an in vitro cellular model simulating CRS. After pretreatment with PLD, EthD-I staining, TUNEL staining, transmission electron microscopy (TEM), and GSDMD-NT detection were performed to evaluate pyroptosis markers. The NLRP3 inflammasome was detected by IF and western blotting (WB). Reactive oxygen species (ROS) were detected by H2DCFDA staining, and mitochondrial membrane potential was evaluated by JC-1 staining. Mitochondrial morphology and structure were observed using TEM. The Nrf2/HO-1 antioxidant signaling pathway was detected using WB. Results: The nasal mucosa structure of patients with CRS exhibited significant damage, with a marked increase in the expression of pyroptosis-related proteins compared with the control group. LPS/ATP co-stimulation resulted in an increased expression of IL-18 and IL-1β in HNEpCs, causing significant damage to nuclear and cell membranes, GSDMD-NT accumulation around the cell membrane, and intracellular NLRP3 inflammasome activation. Furthermore, it led to increased ROS expression, significantly decreased mitochondrial membrane potential, and damaged mitochondrial structure. However, pretreatment with PLD significantly reversed the aforementioned trends and activated the Nrf2/HO-1 antioxidant signaling pathway. Conclusions: The results of this study confirm that NLRP3-mediated pyroptosis plays a crucial role in the pathological process of nasal mucosal impairment in patients with CRS. PLD inhibits NLRP3-mediated pyroptosis, preventing inflammatory damage in HNEpCs of patients with CRS by activating the Nrf2/HO-1 antioxidant signaling pathway, which in turn reduces ROS production and ameliorates mitochondrial damage.
- Open Access
- 27 November 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 321, 117490
Xiaoqinglong decoction improves allergic rhinitis by inhibiting NLRP3-mediated pyroptosis in BALB/C mice
- 27 November 2023
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 321, 117490
Open AccessXiaoqinglong decoction improves allergic rhinitis by inhibiting NLRP3-mediated pyroptosis in BALB/C mice
- Open Access
- 4 May 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (6) , 529-538
Diagnosis and Treatment Strategy of Nasogenic Olfactory Dysfunction
Since the global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a symptom of the onset of SARS-CoV-2, olfactory dysfunction (OD), has attracted tremendous attention. OD is not only a negative factor for quality of life but also an independent hazard and early biomarker for various diseases, such as Parkinson’s and Huntington’s diseases. Therefore, early identification and treatment of OD in patients are critical. Many etiological factors are responsible for OD based on current opinions. Sniffin’Sticks are recommended to identify the initial position (central or peripheral) for OD when treating patients clinically. It is worth emphasizing that the olfactory region in nasal cavity is recognized as the primary and critical olfactory receptor. Many nasal diseases, such as those with traumatic, obstructive and inflammatory causes, can lead to OD. The key question is no refined diagnosis or treatment strategy for nasogenic OD currently. This study summarizes the differences in medical history, symptoms, auxiliary examination, treatment and prognosis of different types of nasogenic OD by analyzing the current studies. We propose using olfactory training after 4–6 weeks of initial treatment for nasogenic OD patients with no significant improvement in olfaction. We hope that our research can provide valuable clinical guidance by systematically summarizing the clinical characteristics of nasogenic OD.
- 4 May 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (6) , 529-538
Open AccessDiagnosis and Treatment Strategy of Nasogenic Olfactory Dysfunction
Since the global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a symptom of the onset of SARS-CoV-2, olfactory dysfunction (OD), has attracted tremendous attention. OD is not only a negative factor for quality of life but also an independent hazard and early biomarker for various diseases, such as Parkinson’s and Huntington’s diseases. Therefore, early identification and treatment of OD in patients are critical. Many etiological factors are responsible for OD based on current opinions. Sniffin’Sticks are recommended to identify the initial position (central or peripheral) for OD when treating patients clinically. It is worth emphasizing that the olfactory region in nasal cavity is recognized as the primary and critical olfactory receptor. Many nasal diseases, such as those with traumatic, obstructive and inflammatory causes, can lead to OD. The key question is no refined diagnosis or treatment strategy for nasogenic OD currently. This study summarizes the differences in medical history, symptoms, auxiliary examination, treatment and prognosis of different types of nasogenic OD by analyzing the current studies. We propose using olfactory training after 4–6 weeks of initial treatment for nasogenic OD patients with no significant improvement in olfaction. We hope that our research can provide valuable clinical guidance by systematically summarizing the clinical characteristics of nasogenic OD.
- Open Access
- 13 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2226
Multimorbidity of Allergic Conditions in Urban Citizens of Southern China: A Real-World Cross-Sectional Study
Background: Extensive knowledge of allergic multimorbidities is required to improve the management of allergic diseases with the industrialization of China. However, the demography and allergen distribution patterns of allergic multimorbidities in China remain unclear, despite the increasing prevalence of allergies. Methods: This was a real-world, cross-sectional study of 1273 outpatients diagnosed with one or more allergic diseases in Guangzhou, the most populated city of southern China, with leading industrial and commercial centers, between April 2021 and March 2022. Seven allergic diseases (allergic rhinitis (AR), asthma (AS)/cough variant asthma (CVA), atopic dermatitis (AD)/eczema, food allergy (FA), allergic conjunctivitis (AC), drug allergy (DA), and anaphylaxis) were assessed. Positive rates of sensitization to different allergens were measured using an allergen detection system of the UniCAP (Pharmacia Diagnostics, Sweden) instrument platform to compare the groups of allergic multimorbidities against a single entity. Results: There were 659 (51.8%) males and 614 (48.2%) females aged from 4 months to 74 years included in the analysis. The study participants who were diagnosed with allergic diseases had an average of 1.6 diagnoses. Overall, 46.5% (592 of 1273) of the patients had more than one allergic condition, and allergic rhinitis was the most common type of multimorbidity. Women were more likely to suffer from an allergic disease alone, whereas allergic multimorbidities were more likely to be diagnosed in men (p = 0.005). In addition, allergic multimorbidities were common in all age groups, with an incidence ranging from 37.1% to 57.4%, in which children and adolescents were more frequently diagnosed with allergic multimorbidities than adults (18–60 years old) (all p < 0.05). Allergic multimorbidity was observed throughout the year. A difference in the positive rate of allergens sensitization and total immunoglobulin E (tIgE) levels between different allergic multimorbidities was observed. Conclusions: Allergic multimorbidities were very commonly found in nearly half of all patients with allergies. The proportion of allergic multimorbidities varied with the type of disease, sex, age, and allergen distribution pattern. These findings may help clinicians to develop “One health” strategies for the clinical management of allergic diseases.
- 13 March 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (6) , 2226
Open AccessMultimorbidity of Allergic Conditions in Urban Citizens of Southern China: A Real-World Cross-Sectional Study
Background: Extensive knowledge of allergic multimorbidities is required to improve the management of allergic diseases with the industrialization of China. However, the demography and allergen distribution patterns of allergic multimorbidities in China remain unclear, despite the increasing prevalence of allergies. Methods: This was a real-world, cross-sectional study of 1273 outpatients diagnosed with one or more allergic diseases in Guangzhou, the most populated city of southern China, with leading industrial and commercial centers, between April 2021 and March 2022. Seven allergic diseases (allergic rhinitis (AR), asthma (AS)/cough variant asthma (CVA), atopic dermatitis (AD)/eczema, food allergy (FA), allergic conjunctivitis (AC), drug allergy (DA), and anaphylaxis) were assessed. Positive rates of sensitization to different allergens were measured using an allergen detection system of the UniCAP (Pharmacia Diagnostics, Sweden) instrument platform to compare the groups of allergic multimorbidities against a single entity. Results: There were 659 (51.8%) males and 614 (48.2%) females aged from 4 months to 74 years included in the analysis. The study participants who were diagnosed with allergic diseases had an average of 1.6 diagnoses. Overall, 46.5% (592 of 1273) of the patients had more than one allergic condition, and allergic rhinitis was the most common type of multimorbidity. Women were more likely to suffer from an allergic disease alone, whereas allergic multimorbidities were more likely to be diagnosed in men (p = 0.005). In addition, allergic multimorbidities were common in all age groups, with an incidence ranging from 37.1% to 57.4%, in which children and adolescents were more frequently diagnosed with allergic multimorbidities than adults (18–60 years old) (all p < 0.05). Allergic multimorbidity was observed throughout the year. A difference in the positive rate of allergens sensitization and total immunoglobulin E (tIgE) levels between different allergic multimorbidities was observed. Conclusions: Allergic multimorbidities were very commonly found in nearly half of all patients with allergies. The proportion of allergic multimorbidities varied with the type of disease, sex, age, and allergen distribution pattern. These findings may help clinicians to develop “One health” strategies for the clinical management of allergic diseases.
- Open Access
- 5 January 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (4) , 376-390
HDAC Downregulation of Xiaoqinglong Decoction in the Treatment of Allergic Rhinitis
Introduction: As one of the most common allergic diseases, allergic rhinitis (AR) has attracted wide attention all over the world. More appropriate treatment of AR should be explored thoroughly. In recent years, traditional Chinese medicine has attracted more attention in AR treatment. As a classical Chinese medicine prescription, Xiaoqinglong decoction (XQLD) has been commonly used in treating AR. Even though its therapeutic effect on AR has been clinically confirmed, more molecular mechanism remains to be further investigated. Our research aimed to investigate the therapeutic mechanism of XQLD for AR management. Methods: The study was evaluated in an ovalbumin sensitized mouse model and liquid chromatography-mass spectrometry was adopted to test the stability of XQLD’s effective components. Results: The results confirmed the stability and safety of the effective components of XQLD. XQLD significantly downregulated the expression of HDACs (HDAC1, HDAC3, and HDAC4) and Th2 inflammatory factors (IL4, IL5, and IL13) in AR mice. XQLD and the HDAC inhibitor JNJ-26481585 promoted the expression of epithelial tight junction proteins (claudin-1 and ZO-1) and decreased the expression of mucins (Muc5ac and Muc5b) in the nasal mucosa of AR mice. Conclusions: In conclusion, our findings present the beneficial effects of XQLD on AR and recovery of the nasal epithelium. We also identify the decreased HDAC as a potential target of XQLD for AR treatment. This study provides an important experimental proof for elucidating the therapeutic mechanism of XQLD.
- 5 January 2023
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 184 (4) , 376-390
Open AccessHDAC Downregulation of Xiaoqinglong Decoction in the Treatment of Allergic Rhinitis
Introduction: As one of the most common allergic diseases, allergic rhinitis (AR) has attracted wide attention all over the world. More appropriate treatment of AR should be explored thoroughly. In recent years, traditional Chinese medicine has attracted more attention in AR treatment. As a classical Chinese medicine prescription, Xiaoqinglong decoction (XQLD) has been commonly used in treating AR. Even though its therapeutic effect on AR has been clinically confirmed, more molecular mechanism remains to be further investigated. Our research aimed to investigate the therapeutic mechanism of XQLD for AR management. Methods: The study was evaluated in an ovalbumin sensitized mouse model and liquid chromatography-mass spectrometry was adopted to test the stability of XQLD’s effective components. Results: The results confirmed the stability and safety of the effective components of XQLD. XQLD significantly downregulated the expression of HDACs (HDAC1, HDAC3, and HDAC4) and Th2 inflammatory factors (IL4, IL5, and IL13) in AR mice. XQLD and the HDAC inhibitor JNJ-26481585 promoted the expression of epithelial tight junction proteins (claudin-1 and ZO-1) and decreased the expression of mucins (Muc5ac and Muc5b) in the nasal mucosa of AR mice. Conclusions: In conclusion, our findings present the beneficial effects of XQLD on AR and recovery of the nasal epithelium. We also identify the decreased HDAC as a potential target of XQLD for AR treatment. This study provides an important experimental proof for elucidating the therapeutic mechanism of XQLD.